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Abstract
Treatment with pegylated interferon alpha-2b (PEGIFN) plus ribavirin (RBV) is standard therapy for patients with chronic
hepatitis C. Although the effectiveness, patients with high titres of group Ib hepatitis C virus (HCV) respond poorly
compared to other genotypes. At present, we cannot predict the effect in an individual. Previous studies have used
traditional statistical analysis by assuming a linear relationship between clinical features, but most phenomena in the clinical
situation are not linearly related. The aim of this study is to predict the effect of PEG IFN plus RBV therapy on an individual
patient level using an artificial neural network system (ANN). 156 patients with HCV group 1b from multiple centres were
treated with PEGIFN (1.5 mg/kg) plus RBV (400–1000 mg) for 48 weeks. Data on the patients’ demographics, laboratory tests,
PEGIFN, and RBV doses, early viral responses (EVR), and sustained viral responses were collected. Clinical data were
randomly divided into training data set and validation data set and analyzed using multiple logistic regression analysis
(MLRs) and ANN to predict individual outcomes. The sensitivities of predictive expression were 0.45 for the MLRs models
and 0.82 for the ANNs and specificities were 0.55 for the MLR and 0.88 for the ANN. Non-linear relation analysis showed that
EVR, serum creatinine, initial dose of Ribavirin, gender and age were important predictive factors, suggesting non-linearly
related to outcome. In conclusion, ANN was more accurate than MLRs in predicting the outcome of PEGIFN plus RBV
therapy in patients with group 1b HCV.
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Introduction
Chronic hepatitis C (CHC) is of global concern because CHC
patients frequently develop liver cirrhosis and hepatocellular
carcinoma (HCC). Eradication of the hepatitis C virus (HCV) is
an effective means of preventing CHC. Pegylated interferon
alpha-2b (PEGIFN) plus ribavirin (RBV) combination therapy
against the HCV is currently standard therapy for patients with
CHC. Although this combination is effective against certain types
of HCV, it is effective in only 50–60% of patients infected with the
IFN-resistant strain of HCV [1]. HCV genotype 1 is common in
the United States [2], Europe, and Japan. In Japan, 70% of CHC
patients are infected with HCV genotype 1b [2–6]. The treatment
outcome of patients infected with HCV genotype 1b is poor
compare to other genotypes and the virus is eradicated from only
50% of these patients [7–11].
Although prolonged treatment with an elevated dose of RBV
increases the efficacy of PEGIFN plus RBV treatment [12], the
response rate is still relatively low. Furthermore, indices for
determining whether to continue or stop treatment are lacking.
Seventy-five % of patients treated with IFN experience systemic
side-effects [1], the treatment of which adds to the cost and
duration of IFN treatment. Therefore, it is important to identify
factors predictive of treatment efficacy. Early viral response (EVR),
a 2-log decrease in the serum HCV RNA level 12 weeks after
commencing therapy, is a useful predictive factor. We also have
demonstrated host and viral predictive factors [13–15].
Current guidelines recommend that treatment be discontinued
for patients who do not achieve viral clearance from sera until 24
weeks after commencing therapy [1]; however, only 50–70% of
patients achieve EVR [1]. Moreover, it is recommended that the
decision to discontinue treatment should be made on an individual
basis according to the patient’s tolerance of therapy and
biochemical or viral responses to treatment [1].
Previous studies, which typically used linear discriminant
analysis provided the significant factors, though were unable to
predict treatment outcomes at the level of the individual patient.
Many clinical analyses have employed classical linear methods
even though most data obtained in clinical settings are confounded
and variables are not linearly related. A recent study demonstrated
that the kinetics of most phenomena in living organisms are non-
linear [16]. For these reasons, most data derived from clinical
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predicting responses at the level of the individual [16].
Artificial neural networks (ANNs) do not suffer from the
problems inherent in traditional prediction methods. An ANN is a
learning system based on a computational technique and has been
used to simulate the neurological processing ability of the human
brain [17]. ANNs recognise complex patterns between inputs and
outputs via the learning process. Once the hidden relationship
between input and output has been learned, an ANN can correctly
predict output from a given input [18,19]. ANNs are considered
more suitable than MLRs for solving problems of the non-linear
type and for analysing complex datasets [20–24]. Notably, ANNs
can provide conclusive predictions at the individual level [16].
Previous reports have demonstrated that ANNs are superior to
classical linear methods in the prediction of responses to
interferon-a and RBV [20,21,23–26]. It is unclear whether the
results of classical linear studies are representative of clinical
conditions because all genotypes and a high number of responders
were included in these studies. Moreover, liver biopsy results were
often used as input data in classical linear studies. Although liver
biopsies are useful, the procedure is associated with a high degree
of risk and a large sampling error [27]. Alternative non-invasive
and low-cost predictive methods are required.
The aims of this study were to develop a new model for
predicting responses to PEGIFN plus RBV combination therapy
in CHC patients infected with HCV genotype 1b by using clinical
and laboratory data and an ANN and to identify factors that have
non-linear relationships with responses.
Results
Response rate and patient backgrounds
One hundred and fifty-six patients (101 men and 55 women;
mean age, 57.6 years; range of age, 18–77 years) received
PEGIFN plus RBV therapy (table 1). Of the 156 patients, 66
patients (42.3%) achieved SVR.
Input factors and Outcome
We used the clinical data to determine input factors X1–X21,
which were used to predict the outcomes of individual patients
using MLR and ANN analysis (table 2). X1–X4 represented the
patient’s sex, age, height, and weight, respectively. X5 and X6
represented previous treatment with interferon and interferon plus
RBV, respectively. X7 and X8 represented the initial doses of
PEGIFN and RBV, respectively. X9–X16 represented laboratory
variables (X9, white blood cell count; X10, red blood cell count;
X11, haemoglobin level; X12, platelet count; X13, serum AST level;
X14, serum ALT level; X15, serum creatinine level; and X16, serum
total cholesterol level). X17 represented the presence of diabetes
mellitus, X18 represented the HCV RNA level, X19 and X20
represented the total amount of administered PEGIFN and RBV,
respectively, and X21 represented EVR, defined as the a 2-log
decrease in the serum HCV RNA 12 weeks after therapy began.
The outcome was SVR, which was determined 24 weeks after
cessation of therapy.
Significant factors for the prediction of SVR
For the prediction of SVR, factor X21 (EVR) was highly
significant and had a high x
2 value (p,0.0001; table 3). Factor X20
(total amount of RBV administrated) was the next most effective
factor (p,0.05). Factors X1 (sex), X9 (serum creatinine level), X15
(ALT level), and X16 (presence of diabetes mellitus) were the next
most effective factors, but their regression coefficients were not
statistically significant. Other factors had little effect on the
response to therapy.
Non-linear relation exists between input factors and SVR
Next, we generated the predictive expression by using MLR
and ANN to predict outcomes from multiple factors as
determined by the aforementioned tests. We randomly divided
the whole data into training data set for generation of the
predictive expressions and validation data set to evaluate their
accuracy (table 4). As shown in table 4, there were no significant
difference in all factors between training data set and validation
data set. The sensitivities were 0.45 in MLR and 0.82 in ANN
(table 5). The specificities were 0.55 in MLR and 0.88 in ANN.
The low frequency of both sensitivity and specificity in MLR and
improved in ANN suggest that a non-linear relationship exists
between inputs and outcomes. We also conducted ROC curve
analysis to evaluate the accuracy of each prediction. To validate
propriety, we analysed the ROC using validation data without
training data. The area under the curves of the ROCs (AUROCs)
of MLR was 0.662 and the mean AUROCs for ANNs was 0.884
(figure 1).
To evaluate the superiority in prediction of ANN, we randomly
divided the all data into training data and validation data for 4
Table 1. Characteristics of patients.
Total n=156
Mean age (range) 57.6 (18–77)
Sex Male, 101; Female, 55
Weight 61.1 (39.4–99.5)
Height 163.7 (143.9–186)
Previous treatment
Interferon Yes: 67 (42.9%) No: 89 (57.1%)
Interferon plus RBV Yes: 26 (16.7%) No: 130 (83.3%)
Initial dose of PEGIFN 87.1 (30–150)
Initial dose of RBV 668 (400–1000)
WBC 4884 (2300–9760)
RBC 456 (319–592)
Hb 14.4 (10.9–17.6)
Plt 16.6 (5.8–39.9)
AST 62 (20–246)
ALT 81 (15–309)
Cre 0.77 (0.47–1.40)
TC 177.6 (92–309)
Diabetes mellitus Yes: 15 (9.6%) No: 124 (79.5%)
Not determined: 17 (10.9%)
HCV RNA level 1842.1 (0.28–7774.1)
Total amount of
PEGIFN (mg/kg/d)
1.15 (0.022–1.889)
Total amount of
RBV (mg/kg/d)
8.27 (0.223–14.545)
SVR of HCV after 12 weeks Yes: 80 (51.3%) No: 76 (48.7%)
Continuous data are expressed as the mean with the range or percentage in
parentheses. WBC: white blood cell count, RBC: red blood cell count, Hb: serum
haemoglobin, Plt: platelet count, AST: asparate aminotransaminase ALT: alanine
transaminase, Cre: creatinine, TC: total cholesterol, SVR: sustained viral
response, HCV: hepatitis C virus.
doi:10.1371/journal.pone.0027223.t001
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the correct answer rate and AUROCs for the ANNs were
significantly greater than that for MLRs (p,0.05) (table 6, 7 and
figure 2, 3).
Relative weights of the input factors
We analyzed relative weights of the input factors to identify
factors that had a significant effect (including both linear and non-
linear relationship) on the result of ANN (figure 4). Relative
Table 2. Factors and outcomes used to predict individual patient outcomes.
Factor
X1: 1=Male, 2=Female X12: Haemoglobin
(g/dL)
X2: Age, 57.6610.3 X13: Plt (610
5/mL)
X3: Height (cm) X14: AST (IU/L)
X4: Weight (kg) X15: ALT (IU/L)
X5: Previous therapy with interferon 0=no, 1=yes X16: Diabetes mellitus 0=no, 1=not determined, 2=yes
X6: Previous therapy with interferon plus RBV 0=no, 1=yes X17: Serum total cholesterol level (mg/dL)
X7: Initial dose of PEGIFN (mg) X18: HCV RNA level before treatment (kIU/mL)
X8: Initial dose of RBV (mg) X19: Total amount of PEGIFN administered (mg/kg/week)
X9: Serum creatinine level (g/dL) X20: Total amount of RBV administered (mg/kg/day)
X10: WBC level (/mL) X21: EVR 0=no, 1=yes
X11: RBC level (610
6/mL)
Outcome
SVR 24 weeks after commencement of treatment 0=no, 1=yes
doi:10.1371/journal.pone.0027223.t002
Table 3. Results of multiple logistic regression analysis.
Factor Regression coefficient
Standard
error x
2 value p value
Constant 3.8391 8.2907 0.21 0.6433
X1 0.9712 0.4989 3.79 0.0516
X2 0.0250 0.0263 0.90 0.3429
X3 20.0117 0.0474 0.06 0.8045
X4 0.0334 0.0437 0.59 0.4439
X5 0.0349 0.2550 0.02 0.8911
X6 0.0216 0.3366 0.00 0.9489
X7 0.0118 0.0254 0.21 0.6438
X8 20.0046 0.0031 2.24 0.1344
X9 23.6052 2.0527 3.08 0.0790
X10 20.0001 0.0002 0.24 0.6227
X11 0.0155 0.0100 2.39 0.1221
X12 20.3129 0.3349 0.87 0.3503
X13 20.0389 0.0549 0.50 0.4789
X14 0.0173 0.0149 1.35 0.2452
X15 20.0151 0.0086 3.10 0.0785
X16 (0) 0.3585 0.4015 0.80 0.3719
X16 (1) 21.1350 0.6219 3.33 0.0680
X17 20.0024 0.0088 0.08 0.7812
X18 0.0007 0.0002 0.72 0.3970
X19 0.5059 0.9554 0.28 0.5965
X20 20.2572 0.1136 5.12 0.0236
X21 1.4625 0.2725 28.80 ,0.0001
doi:10.1371/journal.pone.0027223.t003
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when the test factor (Xtest) is excluded. An Xtest value greater than 1
indicates that it improves the expression, and a value less than 1
indicates that it does not improve the expression. We analysed the
value of all networks and determined the corresponding means
and standard deviations. X21: EVR was the most important
predictive factor in every trial. The means of X1: gender and X2:
age, X3: height, X5: previous therapy with interferon, X8: initial
dose of Ribavirin, X9: serum creatinine, X15: ALT, X16: Diabetes
mellitus, X18: HCV RNA level before treatment were also more
than 1, which indicates that they have non-linear relationships
with response to therapy.
Impact of post-treatment factors in prediction of
treatment
We also tried to predict the effect only using pre-treatment
parameters (without using post-treatment parameters: X19: Total
amount of PEGIFN administered, X20: Total amount of RBV
administered, and X21: EVR), though the sensitivity and specificity
were low (MLR; sensitivity 0.45, specificity 0.49, ANN; sensitivity
0.59, specificity 0.71) (table 8).
Discussion
Interactions between clinical, genetic, and environmental
factors may affect the efficacy of PEGIFN plus RBV combination
Figure 1. ROCs for multiple logistic regression models and
ANN: (A) MLRs, (B) ANNs.
doi:10.1371/journal.pone.0027223.g001
Table 4. Characteristics of patients in training and validation data set.
Total n=156 Training n=99 Validation n=57
Mean age (range) 56.5 59.3
Sex Male, 67; Female, 32 Male, 33; Female, 24
Weight 62.1 59.3
Height 164.1 162.9
Previous treatment
Interferon Yes: 40 No: 59 Yes: 27 No: 30
Interferon plus RBV Yes: 19 No: 80 Yes: 7 No: 50
Initial dose of PEGIFN 85.8 89.5
Initial dose of RBV 662 677
WBC 4895 4864
RBC 459 452
Hb 14.4 14.3
Plt 16.1 17.4
AST 64 57
ALT 88 69
Cre 0.78 0.76
TC 176.3 1763
Diabetes mellitus Yes: 8 No: 74 Not determined: 17 Yes: 7 No: 50 Not determined: 0
HCV RNA level 1957.7 1641.4
Total amount of PEGIFN (mg/kg/d) 1.11 1.22
Total amount of RBV (mg/kg/d) 8.57 7.79
SVR of HCV after 12 weeks Yes: 51 No: 48 Yes: 29 No: 28
Data showed the mean or numbers of the factors.
No significant differences were exist in all factors between training data and validation data.
doi:10.1371/journal.pone.0027223.t004
Table 5. The sensitivity and specificity provided by multiple
logistic regression analysis and ANN.
MLR ANN
Sensitivity 0.45 0.82
Specificity 0.55 0.88
doi:10.1371/journal.pone.0027223.t005
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physicians when interpreting indications for therapy. Although
there are reports on predictors of the response to treatment against
the HCV [28,29], data derived from clinical epidemiology studies
and medical statistics do not always result in correct predictions at
the level of the individual patient. For instance, both male sex and
low total cholesterol level are considered indicative of a good
prognosis [28], but the prognosis for a male who also has a high
total cholesterol level is unknown. In contrast, ANNs can identify
relationships within a patient’s clinical data that may be
overlooked when classical linear approaches are used [16]. MLRs
are powerful tool to find significant factors and provide the key
factors in present our study, though it is not suit to predict the
results by using factors non-linearly correlate. Because ANNs are
trained using existing data, they are more capable of providing
correct answers for individual patients. The ANN also has
theoretical advantages over conventional MLRs. Unlike MLRs,
ANN can predict both linear and non-linear phenomena and can
analyse relationships between many variables at different levels
[25].
The incidence of correct answers and the AUC of the MLRs
differed greatly from that of the ANN. Moreover, it can say that
data used in most previous studies were not validated because
input data sets were used to estimate ROCs. Therefore, we used
validation data sets to estimate ROCs. If we had used only input
data in the ANN, the AUROC would have been equal to 100%
because an ANN can fit input data perfectly. Compared with
MLRs, a well-trained ANN can predict both linear and non-linear
data.
We note that, although the ANN is a useful model, the network
logic of prediction cannot be broken down into simple elements
because ANNs process data in a non-linear way [16,18,25,30–32].
We analysed the relative weights of input factors to address this
issue. The values of each factor affecting the outcome was analysed
(figure 2). EVR was identified as the most important factor. Serum
creatinine, initial dose of Ribavirin, gender and age also had high
values (figure 2).
Both physicians and patients express concern about the risks
associated with treatment because the outcome is difficult to
predict at the time decisions are made. The increased demand for
individualised treatment necessitates new statistics that can be
applied in conjunction with ethical and clinical evidence at the
individual level. ANNs also have potential economic benefits in
that they reduce unnecessary medical treatment.
A report on the classification of patients was published recently
[33]. Although this is a valid strategy, it is difficult to apply under
clinical conditions because the ISDR mutant and Th1:Th2 ratio
must first be determined. Moreover, there are some conflicting
reports on the ISDR mutant [34]. As the aforementioned report
did not performed validation, they should not be compared with
our results; however, the predictive accuracy of our technique is
superior to them.
The predictive expression developed in this study should aid
physicians to advise individual patients on whether to continue
with PEGIFN plus RBV combination therapy. We also tried to
predict the effect only using pre-treatment parameters (table 8).
Compare to the table 5, both sensitivity and specificity were
dramatically improved by adding post-treatment parameter.
Suggesting, post-treatment parameter such as adherence to
treatment might affect to the effect of PEGIFN plus RBV
combination therapy. As the EVR and total amount of RBV were
the most important parameters in our study, the predictive
expression could also be used to determine whether to increase the
dose of RBV. Because we included the total amount of PEGIFN
and RBV in the data sets, the effect of an increased dose can be
simulated. Although the magnitude of the dose effect depends on
patient’s symptoms and exposure to adverse events, our technique
remains a powerful tool for determining the appropriate dose of
PEGIFN and RBV.
Although our predictive expression does not predict responses
perfectly, our results show that the ANN is a valid method for
devising individual treatment regimens in the clinical situation. It
is well known that 100% prediction accuracy is impossible to
achieve because of random error and multiple biases.
As the outcome of PEGIFN plus RBV treatment may be
affected by multiple unknown factors, it is important to update
data continuously and to acquire clinical data such as the patient’s
demographics, medical history, and laboratory test results. Recent
accumulating data revealed the importance of IL28B gene from
genome wide study [35–37]. Especially, very recent data clearly
showed the significance of SNP rs12979860 in IL28B gene in the
prediction of the treatment outcome [38–41]. We could not assess
the effect of them in this study since we have not collected those
data. Further analyses were needed though it may be improve the
accuracy. It is also important to demonstrate that the use of
trained ANNs in routine medical practice increases the quality of
medical care and reduces costs.
Methods
Patients
The study was conducted by the Keio Association for the Study
of Liver Disease (Supporting Information S1). This study was
approved by the Keio University School of Medicine review board
and the permission was obtained (ID number 2010-026). One
hundred and fifty-six CHC patients (101 men and 55 women;
mean age, 57.6 years) infected with genotype 1b HCV and treated
with PEGIFN plus RBV combination therapy from December
2004 to May 2007 who had been assessed for sustained viral
response (SVR) were enrolled and the data were collected. SVR
was defined as an absence of serum HCV RNA 24 weeks after
cessation of therapy.
All patients had HCV genotype 1b and HCV RNA levels in
excess of 100 kIU/mL as measured by quantitative Cobas
Amplicor assays (Roche Diagnostics Co. Ltd, Tokyo, Japan).
Exclusion criteria were pregnant women or women of childbear-
ing potential, nursing mothers, male patients whose partner could
have become pregnant, anaemia, leucopenia, thrombocytopenia,
Table 7. The incidence of correct predictions (%) provided by
the ANN.
ANN 1 ANN 2 ANN 3 ANN 4
Training data set 85.9 83.4 79.6 80.5
Validation data set 74.9 75.4 78.2 80.0
doi:10.1371/journal.pone.0027223.t007
Table 6. The incidence of correct answers (%) provided by
multiple logistic regression analysis.
Trial 1 Trial 2 Trial 3 Trial 4
Correct answers (%) 72.6 64.5 75.8 67.7
doi:10.1371/journal.pone.0027223.t006
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hepatitis B virus or human immunodeficiency virus, autoimmune
hepatitis, primary biliary cirrhosis, and liver dysfunction caused by
drugs.
Some of the patients did not undergo a liver biopsy because not
all of the centres could perform biopsies. All patients were treated
for 48 weeks and were followed up for 48 weeks after treatment.
The purpose of the study and its protocol were explained to all
patients and their written, informed consent was obtained.
PEGIFN plus RBV combination therapy
PEGIFN-a2b (Schering–Plough K.K., Tokyo, Japan) was
administered weekly in doses adjusted for body weight according
to the manufacturer’s recommendations in Japan (45 kg or less,
60 mg; 46–60 kg, 80 mg; 61–75 kg, 100 mg; 76–90 kg, 120 mg; and
91 kg or more, 150 mg). RBV (Schering–Plough K.K.) was
administered once daily in doses adjusted for body weight
according to the manufacturer’s recommendations in Japan
(61 kg or less, 600 mg; 61–80 kg, 800 mg; and 81 kg or more,
1000 mg).
The duration of PEGIFN plus RBV therapy was 48 weeks and
patients were followed-up for the subsequent 48 weeks. Serum
levels of HCV RNA were quantified by amplicor analysis. Blood
was analysed at the beginning of treatment and every 4 weeks
thereafter.
A questionnaire was used to review demographic data (age, sex,
weight, and height), previous treatment, initial dose of PEGIFN,
initial dose of RBV, presence of diabetes mellitus, HCV RNA level
Figure 2. ROCs for four multiple logistic regression models: (A) trial 1, (B) trial 2, (C) trial 3, and (D) trial 4.
doi:10.1371/journal.pone.0027223.g002
Figure 3. ROCs for several expressions of ANNs: (A) ANN1, (B) ANN2, (C) ANN3, and (D) ANN4. Several expressions were generated in
each data set and the each lines show the different expressions of ANNs. Ave. AUCROC shows the average of expressions in each data set.
doi:10.1371/journal.pone.0027223.g003
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and serum concentrations of white blood cells (WBCs), red blood
cells (RBCs), platelets (Plts), asparate aminotransaminase (AST),
alanine transaminase (ALT), creatinine (Cre), and total cholesterol
(TC).
As the data were collected from several centres in various
prefectures, within-centre bias was excluded.
ANN
To develop the ANN, we used three types of network according
to manufacturer’s instruction: multilayer perceptrons (MLPs),
radial-basis function networks (RBFs), and linear networks (LINs).
Details of the ANN and MLP are provided elsewhere [30]. In
brief, a hierarchical ANN consisting of three layers (one input, one
hidden, and one output layer) was used to classify the effect as a
node in the output layer. MLPs were constructed from three layers
(one input, one hidden, and one output layer) to classify effects as a
node in the output layer. RBF units respond to the distance of
points from the centre. The RBF has a hidden layer of radial units,
each of which models a Gaussian response surface. We analyzed
the results of 156 patients from multiple centres and formed
100 000 networks.
Training data set and validation data set
We used same training data set for generating the predictive
expression by using MLR and ANN, and used validation data set
to evaluate the accuracy of the expression generated using training
data set.
Data analysis
Accuracy (correct answer rate), sensitivity, and specificity were
calculated. Also receiver-operating characteristic (ROC) curves for
the MLR and ANN were generated to evaluate their accuracy
[25]. Multiple logistic analysis was performed using JMP version
7.0.1 software (SAS Institute Japan, Co., Ltd, Tokyo, Japan) and
ANN was analysed using Statistica version 06J software (StatSoft
Japan, Co., Ltd, Tokyo Japan).
Relative weights of input factors analysis
The detail of relative weights of input factors analysis
(=sensitivity analysis) were described elsewhere [42]. In brief,
we analysed relative weights of input factors using a leave-one-
input-factor-out (LOFO) in turn with a missing values substitution
procedure, which enables predictions to be made in the absence of
values for each causal factor, and then assessed effects upon ANN
response error. Root mean square error (RMSE) for prediction is
defined as:
RMSE~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ X
Yactual{Ypredicted
   2
n
s
where, n is the number of validation data. Yactual and Yprediced are
the outcomes of actual values and predicted ones, respectively.
RMSE is an estimate of the typical difference between the
predicted and actual values of outcomes. The smaller RMSE the
better the prediction accuracy of the models is.
The network original error was accumulated as RMSEoriginal
and the network was again used with LOFO data and the error
Figure 4. Non-linear analysis of factors for ANNs. Data are expressed as the mean6SD for member networks.
doi:10.1371/journal.pone.0027223.g004
Table 8. The sensitivity and specificity provided by multiple
logistic regression analysis and ANN without post-treatment
parameters.
MLR ANN
Sensitivity 0.45 0.59
Specificity 0.49 0.71
doi:10.1371/journal.pone.0027223.t008
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factors was calculated as RMSELOFO/RMSEoriginal.
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